Skip to main content
. Author manuscript; available in PMC: 2010 Aug 17.
Published in final edited form as: Am J Ophthalmol. 2009 Aug 6;148(5):696–703.e1. doi: 10.1016/j.ajo.2009.06.003

FIGURE 2.

FIGURE 2

CD56bright cells and AC inflammation in a patient with JIA receiving high-dose daclizumab. Grading of AC cells in the right eye of Patient 3 against CD56bright cells (expressed in %) at regular intervals. Note that an expansion in CD56bright cells is associated with a decrease in ocular inflammation whereas a decrease is associated with an increase in intraocular inflammation.